An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study-Reference-Cited by-同舟云学术

An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study

Published:2024-03-18 Issue:6 Volume:65 Page:833-842
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Perrot Aurore¹^ORCID,Delimpasi Sosana²^ORCID,Spanoudakis Emmanouil³^ORCID,Frølund Ulf⁴,Belotti Angelo⁵,Oriol Albert⁶^ORCID,Moreau Philippe⁷^ORCID,McFadden Ian⁸^ORCID,Xia Qing⁸^ORCID,Arora Mukta⁸^ORCID,Dimopoulos Meletios Athanasios⁹^ORCID

Affiliation:

1. Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France

2. General Hospital Evangelismos, Athens, Greece

3. University General Hospital of Evros-Alexandroupolis District, Alexandroupolis, Greece

4. Department of Haematology, Zealand University Hospital, Roskilde, Denmark

5. Hematology Division, ASST Spedali Civili Brescia, Brescia, Italy

6. Hematology Department, Insitut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain

7. Hematology Department, University Hospital, Nantes, France

8. Amgen Inc., Thousand Oaks, CA, USA

9. Section of Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

Funder

Amgen Inc

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2322030

Reference37 articles.

1. Past, Present, and a Glance into the Future of Multiple Myeloma Treatment

2. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

3. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

4. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

5. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study